Full-Time
Develops medical devices for vascular conditions
$95k - $127k/yr
Mid
Company Historically Provides H1B Sponsorship
Alameda, CA, USA
Upload your resume to see how it matches 6 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products include a variety of devices for neuro interventions, such as the Penumbra System and the Penumbra SMART COIL, which are used to address issues like stroke. For peripheral vascular diseases, they offer the Indigo System and related devices. These products are designed to assist healthcare professionals in hospitals and clinics, primarily in Europe and the Americas. Penumbra differentiates itself from competitors by focusing on advanced solutions tailored for specific medical needs and by investing in ongoing research and development to enhance their offerings. The company's goal is to provide effective medical devices that improve patient outcomes in the fields of neurology and vascular surgery.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Alameda, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life
Latest data on Penumbra's CAVT technology to be presented at SIR 2025: STRIDE, STRIKE-PE, and more.
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.
Penumbra recently launched the ACCESS25 Delivery Microcatheter, a single lumen medical device designed to aid physicians in accessing the neurovasculature for the delivery of Penumbra's advanced .020" coil platform.
ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University